CAS 1233515-98-4 Remogliflozin Etabonate-[d6]

General Information
Catalog: BLP-004119
CAS: 1233515-98-4
Molecular Formula: C26H32D6N2O9
Molecular Weight: 528.62

General Information

Catalog: BLP-004119

CAS: 1233515-98-4

Molecular Formula: C26H32D6N2O9

Molecular Weight: 528.62

Chemical Structure

Description	An isotope analogue of Remogliflozin etabonate. Remogliflozin etabonat, prodrug of remogliflozin, is a SGLT2 inhibitor under development for the treatment of type 2 diabetes. Remogliflozin etabonate is a prodrug of remogliflozin, inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney.
Synonyms	ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-({5-methyl-1-[(1,1,1,3,3,3-D6)propan-2-yl]-4-{[4-(propan-2-yloxy)phenyl]methyl}-1H-pyrazol-3-yl}oxy)oxan-2-yl]methyl carbonate
IUPAC Name	ethyl [(2R,3S,4S,5R,6S)-6-[1-(1,1,1,3,3,3-hexadeuteriopropan-2-yl)-5-methyl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl carbonate
Related CAS	442201-24-3 (unlabelled)
Canonical SMILES	CCOC(=O)OCC1C(C(C(C(O1)OC2=NN(C(=C2CC3=CC=C(C=C3)OC(C)C)C)C(C)C)O)O)O
InChI	InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1/i2D3,3D3
InChI Key	UAOCLDQAQNNEAX-BXFPYBFZSA-N
Purity	>98%

Remogliflozin Etabonate-[d6] is a deuterated version of the therapeutic compound used in medical research and application. Here are some key applications of Remogliflozin Etabonate-[d6]:

Pharmacokinetic Studies: Remogliflozin Etabonate-[d6] is used in pharmacokinetic studies to track and analyze drug absorption, distribution, metabolism, and excretion in the body. By substituting hydrogen with deuterium, researchers gain precise insights into metabolic pathways and drug interactions. This information is invaluable for optimizing drug formulations and dosing regimens.

Diabetes Research: In diabetes research, Remogliflozin Etabonate-[d6] aids in understanding the effects of SGLT2 inhibitors, which help control blood sugar levels. It provides a stable isotope-labeled reference for quantifying drug concentration and efficacy in clinical studies. This supports the development and assessment of diabetes therapies aimed at improving glycemic control.

Metabolic Stability Studies: Remogliflozin Etabonate-[d6] is utilized to investigate the metabolic stability of drugs by analyzing deuterium's influence on metabolic rates. This approach helps in identifying potential metabolites and assessing the drug's stability and safety profile. Such studies are critical for ensuring the reliability and effectiveness of pharmaceuticals.

Drug Interaction Analysis: The compound is employed in drug interaction studies to evaluate how SGLT2 inhibitors like Remogliflozin interact with other medications. By using the deuterated form, scientists can more accurately detect and quantify interactions through various analytical techniques.